Appetite News and Research

RSS

GLP-1 weight-loss drugs modulate brain reward circuits to suppress eating for pleasure

A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain.

6 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

Cellular aging in immune cells signals early onset of cognitive depression

Blood tests measuring the aging of certain white blood cells can predict cognitive and mood-related symptoms of depression, rather than physical symptoms.

4 May 2026

Sickness behavior may be a coordinated whole organism immune strategy

Symptoms such as fatigue, loss of appetite, altered sleep, and social withdrawal are often treated as inconvenient side effects of infection.

30 Apr 2026

New research shows weight loss is possible without GLP-1

Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.

30 Apr 2026

Scientists discover how the immune system signals the brain to avoid germs

Researchers from the University of Bonn and University Hospital Bonn uncover vital mechanism for survival

16 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026

When omega-3 may help mental health and when they may not

Investigating omega-3 fatty acids, this review highlights their impact on mental health, inflammation, and the potential for therapeutic use in disorders.

10 Apr 2026

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or experience more nausea and vomiting on GLP-1 drugs. The findings suggest genetics may eventually help predict who responds best to semaglutide or tirzepatide and who is more likely to develop side effects.

9 Apr 2026

Study shows long-term weight benefits for breastfeeding mothers

Breastfeeding does not only affect your weight while you are breastfeeding. Women gain up to 6.5 kilos less on average later in life if they breastfeed for at least three months, according to a new study.

9 Apr 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

Parasites trigger a gut-to-brain signal that cuts food intake during infection

Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.

29 Mar 2026